Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics (NASDAQ:ONCE) in a report issued on Tuesday, December 19th. The firm currently has a buy rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued reports about the company. Wedbush raised Spark Therapeutics from an underperform rating to a neutral rating and decreased their price target for the company from $65.00 to $50.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. Barclays assumed coverage on Spark Therapeutics in a report on Wednesday, September 6th. They issued an overweight rating and a $104.00 target price on the stock. BMO Capital Markets set a $89.00 target price on Spark Therapeutics and gave the stock a buy rating in a report on Tuesday, October 10th. Leerink Swann cut Spark Therapeutics from an outperform rating to a market perform rating and set a $49.00 target price on the stock. in a report on Tuesday, December 12th. Finally, Royal Bank of Canada assumed coverage on Spark Therapeutics in a research report on Thursday, September 14th. They issued an outperform rating and a $100.00 price target for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $76.03.
Spark Therapeutics (NASDAQ ONCE) opened at $52.66 on Tuesday. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75. The stock has a market capitalization of $1,950.00 and a price-to-earnings ratio of -7.31.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period in the prior year, the business posted ($1.07) earnings per share. Spark Therapeutics’s revenue for the quarter was up 45.8% compared to the same quarter last year. analysts forecast that Spark Therapeutics will post -7.55 EPS for the current year.
In other Spark Therapeutics news, insider Barge Joseph La sold 3,309 shares of the company’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $71.31, for a total value of $235,964.79. Following the sale, the insider now directly owns 8,146 shares of the company’s stock, valued at $580,891.26. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the completion of the sale, the chief executive officer now directly owns 250,000 shares in the company, valued at $17,885,000. The disclosure for this sale can be found here. Insiders have sold 62,309 shares of company stock worth $4,621,085 over the last three months. Corporate insiders own 7.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its stake in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Spark Therapeutics during the 2nd quarter worth about $143,000. Teacher Retirement System of Texas acquired a new position in shares of Spark Therapeutics during the 3rd quarter worth about $225,000. Prudential Financial Inc. acquired a new position in shares of Spark Therapeutics during the 3rd quarter worth about $239,000. Finally, Commonwealth Equity Services Inc acquired a new position in shares of Spark Therapeutics during the 3rd quarter worth about $257,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/14/cantor-fitzgerald-analysts-give-spark-therapeutics-once-a-105-00-price-target.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.